Boothbay Fund Management’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.72M Sell
689,001
-48,757
-7% -$128K 0.03% 668
2026
Q2
$1.98M Sell
737,758
-190,155
-20% -$491K 0.03% 724
2026
Q1
$2.06M Buy
927,913
+772,172
+496% +$1.38M 0.03% 605
2025
Q4
$254K Sell
155,741
-331,136
-68% -$510K ﹤0.01% 1531
2025
Q3
$633K Buy
+486,877
New +$422K 0.01% 1039
2022
Q2
– Sell
-71,489
Closed -$224K – 2559
2022
Q1
$224K Hold
71,489
– – 0.01% 1820
2021
Q4
$229K Sell
71,489
-40,555
-36% -$139K 0.01% 1415
2021
Q3
$376K Sell
112,044
-29,389
-21% -$107K 0.01% 1221
2021
Q2
$553K Buy
141,433
+9,599
+7% +$37.9K 0.02% 952
2021
Q1
$530K Buy
+131,834
New +$438K 0.02% 922
2020
Q2
– Sell
-58,368
Closed -$174K – 1095
2020
Q1
$174K Sell
58,368
-17,370
-23% -$58.5K 0.01% 681
2019
Q4
$314K Sell
75,738
-3,657
-5% -$11.5K 0.03% 599
2019
Q3
$257K Buy
+79,395
New +$180K 0.02% 611

Other funds holding OVID

Boothbay Fund Management's OVID Position: Q3 2026 in Review

Boothbay Fund Management reduced its Ovid Therapeutics (OVID) stake by 6.6% in Q3 2026, selling an estimated $128K and leaving 689,001 shares worth $1.72M. The position accounts for 0.03% of the portfolio, ranked #668.

Boothbay Fund Management first reported a position in OVID in Q3 2019 and has held it in 13 quarters since. The position peaked at $2.06M in Q1 2026. 129 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Boothbay Fund Management held 689,001 shares of Ovid Therapeutics worth $1.72M as of Q3 2026.
  • Boothbay Fund Management sold 48,757 Ovid Therapeutics shares in Q3 2026, an estimated $128K.
  • Ovid Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q3 2026, its #668 holding.
  • Boothbay Fund Management first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • Boothbay Fund Management's Ovid Therapeutics position peaked at $2.06M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.